XL AML1/ETO

Translocation/Dual Fusion Probe

Order Number
D-5026-100-OG
Package Size
100 µl
Labels
  
Chromosomes
821

Description

XL AML1/ETO

This product has been replaced by XL t(8;21) plus. Order Number D-5114-100-OG

Clinical Details

Several recurrent balanced translocations and inversions, and their variants, are
recognized in the WHO category acute myeloid leukemia (AML) with recurrent genetic abnormalities. Furthermore, several cytogenetic abnormalities are considered sufficient to establish the WHO diagnosis of AML with myelodysplasia-related features when 20% or more blood or marrow blasts are present.

The t(8;21)(q22;q22) is the most common translocation in de novo AML occurring in up to 20 % of adult and 40 % of pediatric cases of AML. The translocation fuses AML1 (RUNX1) with ETO (RUNX1T1) to produce the AML1/ETO fusion gene located on the derivative 8 chromosome. The prognosis after intensive chemotherapy is better for these patients than for the majority of AML patients.

Clinical Applications

  • Acute Myelogenous Leukemia (AML)

Images

XL AML1/ETO

XL AML1/ETO was hybridized to normal lymphocytes. One metaphase and two interphases are shown.

Expected Patterns

Expected Pattern 1

Normal Cell: Two green (2G) and two orange (2O) signals.

Expected Pattern 2

Aberrant Cell (typical results):
One green (1G), one orange (1O), and two green-orange signals (2GO).

Literature

  • Levanon et al (2001) Gene 262:23-33
  • Varella-Garcia et al (2001) Leukemia 15:1408-1414
  • ? Zhang et al (2002) PNAS 99: 3070-3075

Downloads

Order Now or Request Assistance

Contact Us »

Contact MetaSystems directly or find your local MetaSystems partner.